BR112014012054A2 - métodos de tratamento com deferiprona - Google Patents

métodos de tratamento com deferiprona

Info

Publication number
BR112014012054A2
BR112014012054A2 BR112014012054A BR112014012054A BR112014012054A2 BR 112014012054 A2 BR112014012054 A2 BR 112014012054A2 BR 112014012054 A BR112014012054 A BR 112014012054A BR 112014012054 A BR112014012054 A BR 112014012054A BR 112014012054 A2 BR112014012054 A2 BR 112014012054A2
Authority
BR
Brazil
Prior art keywords
patient
deferiprone
reperfusion injury
methods
application
Prior art date
Application number
BR112014012054A
Other languages
English (en)
Inventor
Arnold Wright Graham
Chalmers Connelly John
Charles Wood John
Spino Michael
Ramesh Ghugre Nilesh
Original Assignee
Apotex Tech Inc
Children's Hospital Los Angeles
Sunnybrook Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Tech Inc, Children's Hospital Los Angeles, Sunnybrook Res Inst filed Critical Apotex Tech Inc
Publication of BR112014012054A2 publication Critical patent/BR112014012054A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

resumo “métodos de tratamento com deferiprona” o presente pedido é direcionado para métodos de tratar ou melhorar isque-mia miocárdica, um evento coronariano agudo, e uma lesão de reperfusão no mio-cárdio que compreende administrar uma quantidade terapeuticamente eficaz de deferiprona ou um sal farmaceuticamente aceitável do mesmo, a um paciente em necessidade do mesmo. o pedido é também direcionado para a redução do risco para lesões de reperfusão no miocárdio, bem como promover a remodelação benéfica do tecido cardíaco em um paciente, que compreende administrar uma quantidade terapeuticamente eficaz de deferiprona ou sal farmaceuticamente aceitável do mesmo a um paciente antes, durante ou após a terapia de reperfusão. o pedido também inclui métodos de selecionar um paciente para o tratamento da lesão de reperfusão, e subsequentemente tratar o paciente selecionado.
BR112014012054A 2011-11-18 2012-11-16 métodos de tratamento com deferiprona BR112014012054A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161561692P 2011-11-18 2011-11-18
US201261591854P 2012-01-27 2012-01-27
PCT/US2012/065663 WO2013075015A1 (en) 2011-11-18 2012-11-16 Methods of treatment with deferiprone

Publications (1)

Publication Number Publication Date
BR112014012054A2 true BR112014012054A2 (pt) 2017-05-30

Family

ID=48430216

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012054A BR112014012054A2 (pt) 2011-11-18 2012-11-16 métodos de tratamento com deferiprona

Country Status (9)

Country Link
US (1) US20140314676A1 (pt)
EP (1) EP2780012A4 (pt)
JP (1) JP2014533697A (pt)
AU (1) AU2012327224A1 (pt)
BR (1) BR112014012054A2 (pt)
CA (1) CA2856229A1 (pt)
IL (1) IL232668A0 (pt)
WO (1) WO2013075015A1 (pt)
ZA (1) ZA201403739B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10694962B2 (en) 2011-06-13 2020-06-30 Cedars-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
WO2012174157A1 (en) 2011-06-13 2012-12-20 Cedars-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
US11590075B2 (en) 2017-02-27 2023-02-28 The University Of Adelaide Methods and products for reducing adhesions
MA50201A (fr) 2017-10-25 2021-04-28 Chiesi Farm Spa Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
EP4042432A4 (en) * 2019-10-10 2022-12-07 Medstar Health Inc. NON-INVASIVE ASSESSMENT OF MICROVASCULAR DISORDERS
EP4120902A1 (en) * 2020-03-20 2023-01-25 Cedars-Sinai Medical Center Prevention and intervention of infarct expansion following hemorrhagic infarctions
JP2024502821A (ja) * 2020-12-31 2024-01-23 アリーナ ファーマシューティカルズ， インコーポレイテッド 処置方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2313270C (en) * 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
EP1297850B1 (en) * 2000-07-05 2015-08-19 Takeda Pharmaceutical Company Limited Medicinal preparations for treating sex hormone-dependent diseases
US20030203915A1 (en) * 2002-04-05 2003-10-30 Xinqin Fang Nitric oxide donors, compositions and methods of use related applications
US7776312B2 (en) * 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
JP2008525468A (ja) * 2004-12-22 2008-07-17 エモリー・ユニバーシティ ポストコンディショニング臓器保護作用を増強する治療補助薬
KR20090035737A (ko) * 2006-08-04 2009-04-10 노파르티스 아게 철 킬레이터를 이용한 내분비 기능장애의 치료
CA2685043A1 (en) * 2007-05-14 2008-11-20 Novartis Ag Use of iron chelator for the treatment of myocardial infarction
US8980223B2 (en) * 2009-05-07 2015-03-17 University Of Cincinnati Methods of preventing ischemic injury using peripheral nociceptive stimulation

Also Published As

Publication number Publication date
EP2780012A1 (en) 2014-09-24
WO2013075015A1 (en) 2013-05-23
JP2014533697A (ja) 2014-12-15
CA2856229A1 (en) 2013-05-23
EP2780012A4 (en) 2015-07-29
IL232668A0 (en) 2014-07-31
US20140314676A1 (en) 2014-10-23
AU2012327224A1 (en) 2013-06-06
ZA201403739B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
BR112014012054A2 (pt) métodos de tratamento com deferiprona
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
EA201400767A1 (ru) Подкожное терапевтическое применение ингибитора dpp-4
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
NZ726366A (en) Syk inhibitors
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
EA201391108A1 (ru) Лечение липодистрофии
UA99953C2 (uk) Лікування релаксином задишки, асоційованої з гострою серцевою недостатністю
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112012015499A2 (pt) método de tratamento de fibrilação atrial
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
BR112012016673A2 (pt) método de tratamento.
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
BR112015018418A2 (pt) métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
ATE543492T1 (de) Behandlung von lungenkrebs
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
BR112013007423A2 (pt) terapia combinada no que diz respeito ao tratamento da infecção por hcv
BR112015030623A2 (pt) agentes citotóxicos para o tratamento de câncer
EP2418956A4 (en) METHOD FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA
AR103118A1 (es) Tratamientos médicos basados en anamorelina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]